Oxurion NV
XBRU:OXUR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.28
6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Oxurion NV
Oxurion NV
Cost of Revenue
Oxurion NV
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oxurion NV
XBRU:OXUR
|
Cost of Revenue
-€159k
|
CAGR 3-Years
34%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Cost of Revenue
-$44.7m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-18%
|
|
|
Galapagos NV
AEX:GLPG
|
Cost of Revenue
-€19.1m
|
CAGR 3-Years
-231%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Cost of Revenue
-€34k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oxurion NV
Glance View
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
See Also
What is Oxurion NV's Cost of Revenue?
Cost of Revenue
-159k
EUR
Based on the financial report for Dec 31, 2023, Oxurion NV's Cost of Revenue amounts to -159k EUR.
What is Oxurion NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
46%
Over the last year, the Cost of Revenue growth was 69%. The average annual Cost of Revenue growth rates for Oxurion NV have been 34% over the past three years , 46% over the past five years .
You don't have any saved screeners yet
